{"id":3759,"date":"2020-11-23T00:00:00","date_gmt":"2020-11-23T00:00:00","guid":{"rendered":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/2020\/11\/23\/cirrhosis-cases-rising-among-women-in-north-america\/"},"modified":"2020-11-24T18:10:16","modified_gmt":"2020-11-24T18:10:16","slug":"cirrhosis-cases-rising-among-women-in-north-america","status":"publish","type":"post","link":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/2020\/11\/23\/cirrhosis-cases-rising-among-women-in-north-america\/","title":{"rendered":"Cirrhosis Cases Rising Among Women in North America"},"content":{"rendered":"<h3>\n<p>Projected future increases in cirrhosis due to alcohol-related liver disease and nonalcoholic fatty liver disease<\/p>\n<\/h3>\n<p><b><\/b><\/p>\n<p><b><\/b><\/p>\n<p>MONDAY, Nov. 23, 2020 (HealthDay News) &#8212; Cirrhosis disease burden in women has increased substantially since 2000, according to a study presented at The Liver Meeting, the annual meeting of the American Association for the Study of Liver Diseases, held virtually from Nov. 13 to 16.<\/p>\n<p>Jennifer A. Flemming, M.D., from Queen&#8217;s University in Kingston, Ontario, Canada, and colleagues used administrative health care data from Ontario to assess the contemporary epidemiology of cirrhosis and liver-related complications in women and projected cirrhosis disease burden to 2040. The analysis was based on data from 65,217 women who were followed for a median of five years.<\/p>\n<p>The researchers found the median age at diagnosis was 57 years, with cirrhosis etiology most commonly resulting from nonalcoholic fatty liver disease (NAFLD; 63 percent), followed by alcohol-related liver disease (ALD; 16 percent), hepatitis C virus (HCV; 10 percent), autoimmune liver disease (AI; 6 percent), and hepatitis B virus (HBV; 5 percent). Incidence rates for cirrhosis increased by 33 percent (average annual percent change [AAPC], 2.5 percent). The changes in incidence rate were greatest for ALD among women born after 1980 (AAPC, 12.8 percent\/year), followed by NAFLD among women born between 1945 and 1964 (AAPC, 8.4 percent\/year). By 2040, the incidence rate for cirrhosis is expected to increase by 8 percent due to increases in ALD (+42 percent) and NAFLD (+34 percent); declines are expected in HCV (\u00e2\u0088\u009291 percent), HBV (\u00e2\u0088\u0092225 percent), and AI\/other (\u00e2\u0088\u0092179 percent). <\/p>\n<p>&#8220;Clearly, a heightened recognition of these key drivers of cirrhosis is essential for both primary care providers and specialists alike and should influence the development and evaluation of public health initiatives,&#8221; Flemming said in a statement.<\/p>\n<p><a href=\"https:\/\/www.aasld.org\/cirrhosis-north-american-women-rise-trend-especially-worrisome-young-women\" target=\"_blank\" rel=\"noopener noreferrer\">Press Release<\/a><\/p>\n<p><a href=\"https:\/\/tlmdx.aasld.org\/\" target=\"_blank\" rel=\"noopener noreferrer\">More Information<\/a><\/p>\n<p><i><\/i><\/p>\n<p><i>Copyright \u00a9 2020 <a href=\"http:\/\/www.healthday.com\/\" target=\"_new\" rel=\"noopener noreferrer\">HealthDay<\/a>. All rights reserved.<\/i><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Projected future increases in cirrhosis due to alcohol-related liver disease and nonalcoholic fatty liver disease<\/p>\n","protected":false},"author":4,"featured_media":3913,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[85],"tags":[411,379,209],"acf":[],"_links":{"self":[{"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/posts\/3759"}],"collection":[{"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/comments?post=3759"}],"version-history":[{"count":0,"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/posts\/3759\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/media\/3913"}],"wp:attachment":[{"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/media?parent=3759"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/categories?post=3759"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/tags?post=3759"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}